PP405 is a promising new treatment for hair loss that activates dormant stem cells in hairfollicles, potentially bypassing the effects of DHT. It is currently in phase 2 trials and could be available between 2027 and 2030, but it is not considered a definitive cure.
JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hairfollicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.
A gel of keratin microspheres promotes hairfollicle growth, showing similar effectiveness to minoxidil in mice. The treatment activateshair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.
PP405 may damage hairfollicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hairfollicle stem cells and may maintain gains without immediate loss, unlike minoxidil.